Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIGHTY: hBRCA84D CAR T cells in Pediatric and Young Adult Sarcoma
NCT07751380Phase 1Recruiting
- Sponsor
- University College London
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hBRCA84D CAR-T cells in rhabdomyosarcoma (RMS), Ewing sarcoma and desmoplastic small round cell tumor (DSRCT), sponsored by University College London. Primary endpoints: Safety of administering the ATIMP at 28 days and Number of therapeutic products generated and the number of ATIMPs infused after successful manufacture at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
hBRCA84D CAR-T cells
03
Conditions
rhabdomyosarcoma (RMS)Ewing sarcomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT07751380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751380.